MedTrace Logo

Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area

NCT06256445 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2026-01-22

No results posted yet for this study

Summary

To Evaluate Efficacy and Safety of AYP-101 S.C injection for the Reduction of Submental Fat in Adults

Conditions

  • Healthy

Interventions

DRUG

Polyene Phosphatidylcholine

Formulated as an injectable solution containing Polyene Phosphatidylcholine at concentration of 25 mg/mL

DRUG

Matching placebo of AYP-101

Phosphate buffered saline placebo for injection

Sponsors & Collaborators

  • AMIpharm Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Beomjoon Kim, MD · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-26
Primary Completion
2024-07-05
Completion
2025-10-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06256445 on ClinicalTrials.gov